(RCUS) Arcus Biosciences, Inc. Business Model Canvas Research

Arcus Biosciences, Inc. holds an Abmuno Therapeutics LLC license on an anti-CD39 antibody, a checkpoint target being studied across multiple solid tumors. This adds one more external partner to Arcus Biosciences, Inc.'s pipeline mix and broadens its deal base beyond its core immuno-oncology programs.

• Anti-CD39 license from Abmuno Therapeutics LLC
• Targets multiple cancers
• Supports pipeline expansion

Arcus Biosciences, Inc. licensed anti-CD39 antibody development to WuXi Biologics, adding outside support for research, process development, and manufacturing scale-up. This partnership helps Arcus keep CD39 work moving while using WuXi Biologics' biologics development platform and global manufacturing network.

• License-backed anti-CD39 collaboration
• Supports development work
• Strengthens external manufacturing capacity

Arcus Biosciences uses biomarker-led trial design and clinical-development partnerships to narrow enrollment to patients most likely to respond, and the Strata Oncology collaboration helps refine that selection. This can lift response rates and cut trial waste by matching the right patients to the right study from the start.

• Strata supports biomarker-guided enrollment.
• Better selection can improve response rates.
• It also speeds trial execution.

Arcus runs partnered development management across 5 key counterparties, coordinating AstraZeneca, BVF Partners, Taiho, Abmuno, and WuXi Biologics. This alliance work supports funding, speeds execution, and helps move multiple clinical and licensing programs in parallel.

• 5 active collaboration touchpoints

• Cross-partner execution and milestone control

• Alliance management tied to funding speed

Arcus Biosciences, Inc. treats its partnership network as a key resource: AstraZeneca, BVF Partners, Strata Oncology, Taiho, Abmuno, and WuXi Biologics give it 6 external links that extend R&D, clinical, and manufacturing capacity beyond its own headcount. That matters for a small biotech, because partner-funded work can push more programs forward without building every function in-house.

• 6 named partners
• Expands development capacity
• Supports external manufacturing and R&D

Arcus Biosciences, Inc. is headquartered in Hayward, California, and the site anchors corporate, scientific, and administrative work. It also helps coordinate research and clinical development across the pipeline, keeping teams aligned from discovery through late-stage execution.

• Hayward HQ centralizes core functions
• Supports research and clinical coordination
• Backs company-wide operating control

Arcus Biosciences builds several programs for combination use, including zimberelimab plus domvanalimab and other pathway-targeted agents. The goal is simple: raise response rates and widen clinical differentiation versus single-agent or same-class regimens.

• Built for multi-drug use
• Zimberelimab and domvanalimab paired
• Targets higher efficacy and differentiation

Arcus Biosciences can move assets with external collaborators and licensees, sharing development cost and risk while widening trial reach. That matters in a capital-heavy space: the company can tap partner networks to push more programs toward approval without funding every step alone.

• Shares cost and clinical risk
• Expands trial and market reach
• Improves odds of approval

Arcus Biosciences, Inc. keeps customer ties tight through ongoing trial readouts and interim data, so sites and partners can steer next steps fast. This is a high-touch, research-led relationship built on frequent feedback, not one-off transactions.

• Interim data guides trial changes
• Study sites shape next steps
• Partner input stays central

Arcus Biosciences, Inc. manages customer relationships through long-term licensing contracts tied to development milestones, so every partner deal needs tight tracking of trial progress, payments, and decision points. In 2025/2026, this model stayed milestone-driven and governance-heavy, with value released only as partnered programs clear agreed stage gates.

• Long-term licensing contracts
• Milestone-based payments
• Active partner governance
• Ongoing performance tracking

Peer-reviewed publications let Arcus Biosciences, Inc. publish clinical and translational results in journals, which strengthens trust in its pipeline and MoAs. They also support partnering and trial enrollment by giving physicians and investors third-party evidence to assess efficacy and safety.

• Builds credibility for lead assets
• Supports BD and trial recruitment
• Validates mechanism with journal review

Arcus Biosciences, Inc. uses Corporate Business Development to source licensing, collaboration, and out-licensing deals, which is vital for a clinical-stage company with no mature product sales. In 2025, the company still relied on partnership income, not product revenue, to fund R&D, so external deal flow is a core channel for capital and pipeline growth.

• Drives non-dilutive capital
• Supports pipeline expansion
• Manages licensing talks

Oncology investigators are a key customer segment for Arcus Biosciences, Inc. because they decide trial uptake, shape protocol execution, and drive publication credibility. That matters in a market where cancer caused about 9.7 million deaths in 2022, so expert investigators are central to patient access and enrollment.

• Drive trial adoption and execution
• Boost publication credibility
• Expand patient access

Specialty cancer-drug licensees are biopharma partners that want differentiated mechanisms and development rights, not just a product. Arcus Biosciences, Inc.’s anti-CD39 arrangements show this segment: a partner pays for access to novel immuno-oncology biology, then shares risk while keeping the option to build a broader oncology franchise.

• Buy novel mechanisms, not me-too drugs
• Want rights to develop and commercialize
• Use deal structures to spread trial risk

For Arcus Biosciences, Inc., this customer group is most relevant when a program can stand out clinically and support follow-on combos across solid tumors.

Arcus Biosciences, Inc. carries partner and license costs tied to shared program funding, milestone payments, and legal/admin work that comes with running alliances. These expenses move with alliance execution, so when partnered trials expand, the cost base rises too.

• Shared program costs drive cash use
• Contract terms create fixed commitments
• Partner oversight adds legal expense

Arcus Biosciences, Inc. carries corporate overhead for headquarters, legal, finance, HR, and compliance, so general and administrative costs stay meaningful even when drug programs are still in development. As a public company, it also pays for SEC reporting, audit, board, and governance work, which makes G&A a steady cash drain.

• HQ and back-office support
• Legal, finance, HR, compliance
• Public-company reporting and audit
• Board and governance costs

This cost line is mostly fixed, so it does not scale down fast when spending shifts to R&D. That means Arcus must keep enough cash on hand to cover recurring overhead while it funds clinical work.

Arcus Biosciences, Inc. uses partner-funded research support to share discovery and trial costs before approval, which lowers cash burn and stretches its R&D budget. In 2025, this mattered because oncology programs still required heavy spend while collaboration reimbursements helped offset the load.

• Partners share R&D costs
• Offsets trial and discovery spend
• Most valuable pre-approval

Arcus Biosciences, Inc.’s long-term revenue upside is tied to approved cancer drugs; today it still has no commercial product sales, so launch success is the key driver. Royalties can also come from partnered programs, but only if those candidates reach market and generate sales.

• No product sales yet
• Revenue depends on approvals
• Royalties from partners possible